Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
No articles found.
vTv Therapeutics is a clinical-stage biopharmaceutical company engaged in the disc...
vTv Therapeutics is a clinical-stage biopharmac...
Cue Biopharma is an innovative clinical stage immunotherapy company developing a n...
Cue Biopharma is an innovative clinical stage i...
NanoString Technologies is a leading provider of life science tools for translatio...
NanoString Technologies is a leading provider o...
BridgeBio finds, develops, and delivers breakthrough medicines for genetic disease...
BridgeBio finds, develops, and delivers breakth...
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, dev...
Cytokinetics is a late-stage biopharmaceutical ...
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology comp...
Amicus Therapeutics (Nasdaq: FOLD) is a global,...
CytomX Therapeutics develops Probody⢠therapeutics for the treatment of cancer. ...
CytomX Therapeutics develops Probody⢠therape...
INmune Bio Inc. is a clinical stage biotechnology company that is developing new i...
INmune Bio Inc. is a clinical stage biotechnolo...
Join the National Investor Network and get the latest information with your interests in mind.